Abstract Aims/hypothesis Whether sodiumglucose co-transporter 2 inhibitors (SGLT2is) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are cost-effective based solely on their cardiovascular and kidney benefits is unknown
Tsai T, Hsu T, Chen C, Cheng J, Chiou M, Huang C, et al
The remaining 15 to 20 percent attempt complete discontinuation
Research shows women who enter pregnancy with obesity or develop gestational diabetes experience even larger metabolic shifts postpartum
High NNMT, as often seen in obesity, may be associated with marks favouring fat storage
The dose-response lines were fitted using least-squares linear regression, and their 95% confidence intervals were calculated according to the previously described method